RxDoctor Payments Data

Antonia Ahern, MD

Neurology · Greensboro, NCNPI 1295053742

Payments from drug & device makers

$34,169in general payments, 2019–2025

Across 395 payments — averaging $86.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$28K
  • Teva Pharmaceuticals USA, Inc.$490
  • Biogen$458
  • UCB, Inc.$436
  • Novartis$421
  • AstraZeneca$421
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$7,44198%
  • Education$1602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)113$28,019
Teva Pharmaceuticals USA, Inc.13$490
Biogen22$458
UCB, Inc.18$436
Novartis33$421
AstraZeneca(2 entities)14$421
Pfizer20$374
EMD Serono, Inc.6$269
E.r. Squibb & Sons, L.L.C.2$228
Jazz Pharmaceuticals Inc.9$197
Lilly USA, LLC8$171
Eisai Inc.8$143
Neurocrine Biosciences, Inc.6$129
Sanofi7$122
Amgen8$109
Lundbeck LLC5$108
Argenx US, Inc.6$103
Acadia Pharmaceuticals Inc6$99
Biohaven Pharmaceuticals, Inc.1$96
SK Life Science, Inc.4$92
GE HealthCare5$86
Medtronic2$86
Bristol Myers Squibb4$74
Harmony Biosciences LLC4$73
Philips North America LLC3$66
Otsuka America Pharmaceutical, Inc.3$65
Akcea Therapeutics, Inc.1$63
Impel Pharmaceuticals Inc.2$62
Takeda Pharmaceuticals U.S.A., Inc.2$61
Merz Pharmaceuticals, LLC3$61
Neurelis, Inc.3$59
Corium, LLC3$52
Axsome Therapeutics, Inc.3$50
Avion Pharmaceuticals3$50
Tanabe Pharma America, Inc.3$48
Supernus Pharmaceuticals, Inc.3$48
Genentech USA, Inc.2$47
TG Therapeutics, Inc.2$45
Novo Nordisk3$42
Amneal Pharmaceuticals LLC2$41
CSL Behring2$39
Scilex Pharmaceuticals Inc.2$38
Vanda Pharmaceuticals Inc.2$37
Biohaven Pharmaceutical Holding Company Ltd.2$36
Boston Scientific2$32
Noctrix Health, Inc.1$28
Alnylam Pharmaceuticals Inc.2$27
Promius Pharma LLC2$25
Sanofi-aventis U.S. LLC1$23
Kyowa Kirin, Inc.1$20
GRT US Holding, Inc.1$19
Mallinckrodt Enterprises LLC1$18
Acorda Therapeutics, Inc1$18
Banner Life Sciences, LLC1$17
Upsher-smith Laboratories LLC1$17
Sandoz1$17
Aprecia Pharmaceuticals, LLC1$16
Collegium Pharmaceutical, Inc.1$16
MDD US Operations, LLC1$14
Assertio Therapeutics, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,169 in reported general payments places this provider in the 75th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$136,549
Medicare patients
132
Services billed
23,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm139$109,488
Nurtec OdtRimegepant Sulfate31$49,765
Ajovy AutoinjectorFremanezumab-Vfrm42$32,799
BotoxOnabotulinumtoxina25$32,592
UbrelvyUbrogepant22$29,138
Aimovig AutoinjectorErenumab-Aooe19$18,343
Trokendi XrTopiramate24$17,295
QuliptaAtogepant14$15,555
Sumatriptan Succinate61$4,439
Memantine Hcl130$3,060
Gabapentin118$2,905
Donepezil Hcl195$1,788
Acetazolamide14$1,328
RizatriptanRizatriptan Benzoate89$1,323
Carbidopa-LevodopaCarbidopa/Levodopa38$1,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta$28,019$77,28561 claims
PfizerNurtec Odt$374$49,76531 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$48$17,29524 claims
Upsher-smith Laboratories LLCTopiramate$17$49076 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 566 neurology providers in North Carolina.

Other neurology in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →